Drugmakers kick off 2021 with 500 U.S. price hikes

[DearWallstreet.com] DWS Daily on Jan 04, 2021 EMAIL}/redirect [Drugmakers kick off 2021 with 500 U.S. price hikes Michael Erman]( Image]( By Michael Erman NEW YORK (Reuters) - Drugmakers including Abbvie Inc and Bristol Myers Squibb raised U.S. list prices on more than 500 drugs to kick off 2021, according to an analysis by health care research firm 46brooklyn. The hikes come as drugmakers are reeling from effects of the COVID-19 pandemic, which has reduced doctor visits and demand for some drugs. They are also fighting new drug price-cutting rules from the Trump administration, which would reduce the industry's profitability. They include more than 300 price increases from companies like Pfizer and GlaxoSmithKline reported by Reuters late last week. Nearly all the increases were below 10%, and the median hike was 4.8%, down slightly from last year, 46brooklyn said . The firm's analysis is based on data from Elsevier's Gold Standard Drug Database. Abbvie raised prices on around 40 drugs including a 7.4% hike on rheumatoid arthritis treatment Humira, the world's top-selling drug. Revenue from Humira is expected to top $20 billion next year. Bristol Myers hiked prices on around a dozen drugs, including cancer drugs Revlimid and Opdivo by 4.5 percent and 1.5 percent, respectively. It hiked the price of blood thinner Eliquis by 6 percent. It said in a statement that it only raised prices on drugs with ongoing clinical research. It expects net prices, which include rebates and other discounts, to fall this year. Drug price increases have slowed substantially since 2015, both in terms of the size of the hikes and the number of drugs affected. However, 46brooklyn said its analysis of Medicaid data shows the average cost per branded drug is still ticking up.    "Over time, we end up cycling out cheaper brands designed to treat large populations, and replacing them with expensive brands designed to treat smaller populations," wrote Eric Pachman, president of 46brooklyn. "With price increases losing their impact, launch prices will be the primary driver of U.S. drug list price inflation." (Reporting by Michael Erman; Editing by David Gregorio) [Slack outage disrupts remote working for users]( (Reuters) - Workplace messaging app Slack Technologies Inc said that users were facing connectiv...([Continue Reading]( EMAIL}/redirect [Volkswagen hires utility executive to lead electric charging unit]( FRANKFURT (Reuters) - Volkswagen has hired Elke Temme, a long-time executive at Germany's top ut...([Continue Reading]( [Wall Street places bet on solid revenue growth for Airbnb, DoorDash]( By Noor Zainab Hussain and Tanvi Mehta (Reuters) - A slew of brokerages initiated ...([Continue Reading]( EMAIL}/redirect GENERAL NOTICE AND DISCLAIMER - PLEASE READ CAREFULLY THE FOLLOWING NOTICE AND DISCLAIMER MUST BE READ AND UNDERSTOOD AND YOU MUST AGREE TO THE TERMS CONTAINED THEREIN BEFORE USING THIS WEBSITE OR SUBSCRIBING TO OUR NEWSLETTER.This is a PAID ADVERTISEMENT provided to customers/subscribers of dearwallstreet. Although we have sent you this email, dearwallstreet does NOT specifically endorse this product nor is it responsible for the content of this message. Furthermore, we make no guarantee or warranty about what is advertised above. DISCLAIMER: In accordance with Section 17(b) of the Securities Act of 1933, you are hereby advised that dearwallstreet. "DWS" is receiving a fee of over $1000.00 in cash, from an independent third party as compensation for the distribution of this message. DWS has not determined if the statements and opinions of the advertiser are accurate, correct or truthful. The purpose of this message, like any advertising, is to provide publicity for the advertising company, its products or services. You should not rely on the information presented; you should do independent research to form your own opinion and decision. Information contained in our disseminated emails does not constitute investment, legal or tax advice upon which you should rely. The purchase of high-risk securities may result in the loss of your entire investment. Advertisements received by you are not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the States or other jurisdictions in which the security is eligible for sale. Advertisements distributed through disseminated emails are not disclosure documents. If you are considering purchasing any securities of an advertised company, you should call your State Securities Administrator to determine if the security may be sold in your State. Many companies have information filed with State securities regulators who may be able to supply you with additional information. You also should read and review, if and to the extent available, any information concerning an advertised company available at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at and the Financial Industry Regulatory Authority (the "FINRA") at . We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud at as well as related information published by the NASD on how to invest carefully. You are responsible for verifying all claims and conducting your own due diligence. You agree and acknowledge that any hyperlinks to the website of (1) an advertised company, (2) the party issuing or preparing the information for the advertised company, or (3) other information contained in our disseminated emails is provided only for your reference and convenience. We are not responsible for the accuracy or reliability of these external sites, nor are we responsible for the content, advertising, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated email or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on us, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink. You also acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser. You acknowledge that you will consult with your own advisers regarding any decisions as to any advertised company. dearwallstreet.com is affilated with interactiveoffers.com. Rua Frei Tomé de Jesus n. 18 1 dto. Lisboa Lisboa 1700-215 PORTUGAL [Unsubscribe]( [Change subscriber options](